Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.30 -2.1%	$11.29	$3.98 ▼ $13.37	$1.87B	1.92	2.04 million shs	1.10 million shs
ATAI atai Life Sciences	$3.98 +0.1%	$3.10	$1.03 ▼ $4.40	$852.00M	1.54	3.67 million shs	2.51 million shs
BEAM Beam Therapeutics	$16.05 -1.9%	$18.81	$13.52 ▼ $35.25	$1.62B	2.22	2.09 million shs	2.29 million shs
CNTA Centessa Pharmaceuticals	$17.28 -0.3%	$14.98	$9.60 ▼ $19.09	$2.31B	1.48	964,563 shs	595,781 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+1.21%	-0.79%	+20.89%	+38.17%	+161.12%
ATAI atai Life Sciences	-1.98%	-3.87%	+22.91%	+107.85%	+203.05%
BEAM Beam Therapeutics	-4.39%	-3.02%	-21.20%	-5.05%	-34.60%
CNTA Centessa Pharmaceuticals	-1.42%	+1.34%	+10.52%	+35.26%	+40.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.2553 of 5 stars	1.4	1.0	4.2	1.4	1.7	0.6
ATAI atai Life Sciences	2.8558 of 5 stars	3.7	3.0	0.0	2.1	1.7	0.6
BEAM Beam Therapeutics	2.521 of 5 stars	3.5	0.0	0.0	3.6	2.5	0.6
CNTA Centessa Pharmaceuticals	2.1625 of 5 stars	3.5	1.0	0.0	1.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	0.65% Upside
ATAI atai Life Sciences	3.40	Buy	$11.25	183.02% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	201.99% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	62.58% Upside

Current Analyst Ratings Breakdown

Latest ATAI, ADPT, CNTA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
7/30/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $15.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/29/2025	ATAI atai Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
7/28/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.46	N/A	N/A	$1.18 per share	10.42
ATAI atai Life Sciences	$310K	2,748.39	N/A	N/A	$0.67 per share	5.93
BEAM Beam Therapeutics	$63.52M	25.55	N/A	N/A	$10.35 per share	1.55
CNTA Centessa Pharmaceuticals	$15M	154.30	N/A	N/A	$2.58 per share	6.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
ATAI atai Life Sciences	-$149.27M	-$0.69	N/A	N/A	N/A	N/A	-85.43%	-64.38%	N/A
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	N/A

Latest ATAI, ADPT, CNTA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ATAI atai Life Sciences	-$0.12	-$0.14	-$0.02	-$0.14	N/A	$0.72 million
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
ATAI atai Life Sciences	0.02	4.02	4.07
BEAM Beam Therapeutics	N/A	6.75	6.75
CNTA Centessa Pharmaceuticals	0.32	10.11	10.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ATAI atai Life Sciences	28.41%
BEAM Beam Therapeutics	99.68%
CNTA Centessa Pharmaceuticals	82.01%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ATAI atai Life Sciences	26.80%
BEAM Beam Therapeutics	3.50%
CNTA Centessa Pharmaceuticals	7.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
ATAI atai Life Sciences	80	214.34 million	146.65 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.91 million	124.42 million	Optionable

ATAI, ADPT, CNTA, and BEAM Headlines

Recent News About These Companies

Piper Sandler Remains a Buy on Centessa Pharmaceuticals (CNTA)

August 19 at 1:13 PM | theglobeandmail.com

FY2025 Earnings Estimate for CNTA Issued By Chardan Capital

August 19 at 2:59 AM | marketbeat.com

What is Chardan Capital's Forecast for CNTA FY2025 Earnings?

August 19 at 2:33 AM | americanbankingnews.com

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares

August 17 at 8:17 PM | marketbeat.com

Leerink Partnrs Has Negative Outlook of CNTA FY2025 Earnings

August 17 at 10:27 AM | marketbeat.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Lowered to "Sell" Rating by Wall Street Zen

August 17 at 2:30 AM | marketbeat.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Receives Buy Rating from Chardan Capital

August 14, 2025 | marketbeat.com

Regents of The University of California Buys Shares of 81,884 Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

August 14, 2025 | marketbeat.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Announces Earnings Results, Misses Expectations By $0.04 EPS

August 13, 2025 | marketbeat.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Given "Buy" Rating at Chardan Capital

August 13, 2025 | americanbankingnews.com

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives $28.10 Average PT from Analysts

August 13, 2025 | americanbankingnews.com

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

August 12, 2025 | finanznachrichten.de

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

August 12, 2025 | globenewswire.com

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Recommendation of "Buy" by Brokerages

August 11, 2025 | marketbeat.com

Centessa Pharmaceuticals (CNTA) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

XTX Topco Ltd Purchases 18,377 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

August 6, 2025 | marketbeat.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% - Here's What Happened

August 5, 2025 | marketbeat.com

TD Asset Management Inc Sells 53,592 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

August 2, 2025 | marketbeat.com

Truist Initiates Buy on Centessa Pharmaceuticals (CNTA) with $30 PT, Cites Orexin Drug Potential

August 1, 2025 | msn.com

Mario Alberto Accardi Sells 8,322 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock

July 31, 2025 | marketbeat.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 9.2% - Still a Buy?

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, ADPT, CNTA, and BEAM Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.30 -0.27 (-2.11%)

Closing price 03:59 PM Eastern

Extended Trading

$12.30 0.00 (0.00%)

As of 04:10 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

atai Life Sciences NASDAQ:ATAI

$3.98 +0.01 (+0.13%)

Closing price 03:59 PM Eastern

Extended Trading

$3.94 -0.03 (-0.75%)

As of 04:16 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Beam Therapeutics NASDAQ:BEAM

$16.05 -0.31 (-1.87%)

Closing price 03:59 PM Eastern

Extended Trading

$16.22 +0.17 (+1.06%)

As of 04:15 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$17.28 -0.06 (-0.32%)

Closing price 03:59 PM Eastern

Extended Trading

$17.52 +0.24 (+1.39%)

As of 04:10 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time